Joe Wylie
COMING ON top of the $153m acquisition of Aegerion as recently as September 2019, Amryt Pharma’s current $375m merger with Chiasma represents another major step for the company. As Amryt lost $106m last year, investors will be watching closely to see how CEO Joe Wiley performs and whether he really can deliver on the $1bn... Read more »
To access this content, you must be a Phoenix subscriber.
Get access to The Phoenix online for as low as €1.50 per week. Read all the regular online only Phoenix stories AND receive the packed digital edition every fortnight (25 per year). Great value for so many inside stories!
